Celator Pharmaceuticals, Inc. is an oncology-focused biopharmaceutical company. The Company is engaged in developing products to improve patient outcomes in cancer. The Company's technology platform, CombiPlex, enables the design and evaluation of optimized combinations incorporating traditional chemotherapies, as well as molecularly targeted agents to deliver anti-cancer activity. The Company's product, VYXEOS, a nano-scale liposomal formulation of cytarabine:daunorubicin, in Phase III clinical testing for the treatment of acute myeloid leukemia. The Company also conducted clinical development efforts on CPX-1, a nano-scale liposomal formulation of irinotecan:floxuridine for the treatment of colorectal cancer; and has a preclinical stage product candidate CPX-8, a hydrophobic docetaxel prodrug nanoparticle formulation. The Company operates in the United States and Canada.
Industry, Sector and Symbol:
- Sector: Healthcare
- Industry: Biotechnology & Medical Research - NEC
- Sub-Industry: N/A
- Symbol: NASDAQ:CPXX
- CUSIP: N/A
- Web: N/A
- 50 Day Moving Avg: $28.68
- 200 Day Moving Avg: $12.63
- Trailing P/E Ratio: N/A
- Foreward P/E Ratio: -91.64
- P/E Growth: 0.00
- Return on Equity: -75.03%
- Return on Assets: -46.70%
Frequently Asked Questions for Celator Pharmaceuticals (NASDAQ:CPXX)
What is Celator Pharmaceuticals' stock symbol?
Celator Pharmaceuticals trades on the NASDAQ under the ticker symbol "CPXX."
How were Celator Pharmaceuticals' earnings last quarter?
Celator Pharmaceuticals Inc (NASDAQ:CPXX) announced its earnings results on Tuesday, May, 10th. The company reported ($0.16) earnings per share (EPS) for the quarter, missing the Thomson Reuters' consensus estimate of ($0.15) by $0.01. View Celator Pharmaceuticals' Earnings History.
Who are some of Celator Pharmaceuticals' key competitors?
Some companies that are related to Celator Pharmaceuticals include Incyte Corporation (INCY), Quintiles Transitional Holdings (Q), Alkermes PLC (ALKS), Alnylam Pharmaceuticals (ALNY), Qiagen N.V. (QGEN), Seattle Genetics (SGEN), Ionis Pharmaceuticals (IONS), Icon Plc (ICLR), United Therapeutics Corporation (UTHR), Charles River Laboratories International (CRL), PRA Health Sciences (PRAH), Exact Sciences Corporation (EXAS), PAREXEL International Corporation (PRXL), Bio-Techne Corp (TECH), ACADIA Pharmaceuticals (ACAD), WuXi PharmaTech (Cayman) (WX), Portola Pharmaceuticals (PTLA) and INC Research Holdings (INCR).
How do I buy Celator Pharmaceuticals stock?
Shares of Celator Pharmaceuticals can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Celator Pharmaceuticals' stock price today?
MarketBeat Community Rating for Celator Pharmaceuticals (NASDAQ CPXX)MarketBeat's community ratings are surveys of what our community members think about Celator Pharmaceuticals and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.
One share of Celator Pharmaceuticals stock can currently be purchased for approximately $30.24.
Earnings History for Celator Pharmaceuticals (NASDAQ:CPXX)Earnings History by Quarter for Celator Pharmaceuticals (NASDAQ CPXX)
(Data available from 1/1/2011 forward)
|Date||Quarter||Consensus Estimate||Actual EPS||Revenue Estimate||Actual Revenue||Release Link||Conference Call||Details|
Earnings Estimates for Celator Pharmaceuticals (NASDAQ:CPXX)
Current Year EPS Consensus Estimate: $-0.60 EPS
Next Year EPS Consensus Estimate: $-0.33 EPS
Dividend History for Celator Pharmaceuticals (NASDAQ:CPXX)
No dividend announcements for this company have been tracked by MarketBeat.com
Insider Trading and Institutional Ownership History for Celator Pharmaceuticals (NASDAQ:CPXX)Insider Trades by Quarter for Celator Pharmaceuticals (NASDAQ:CPXX)
(Data available from 1/1/2013 forward)
|Transaction Date||Insider Name||Title||Buy/Sell||Number of Shares||Average Share Price||Total Transaction||Details|
|12/3/2015||Scott D Morenstein||Director||Buy||5,000||$1.87||$9,350.00|| |
|10/6/2015||Scott Thomas Jackson||CEO||Buy||14,450||$1.74||$25,143.00|| |
|10/5/2015||Fred M Powell||CFO||Buy||13,700||$1.78||$24,386.00|| |
|10/1/2015||Life Sciences Gp Ll Valence II||insider||Buy||12,200||$1.64||$20,008.00|| |
|11/18/2014||Fred M Powell||CFO||Buy||6,000||$2.20||$13,200.00|| |
|11/18/2014||Michael R Dougherty||Director||Buy||20,000||$2.15||$43,000.00|| |
|11/18/2014||Scott Thomas Jackson||CEO||Buy||10,000||$2.20||$22,000.00|| |
|5/15/2014||Fred M Powell||CFO||Buy||2,500||$2.50||$6,250.00|| |
|12/17/2013||Fred M Powell||CFO||Buy||2,500||$3.50||$8,750.00|| |
|12/17/2013||Scott Thomas Jackson||CEO||Buy||3,000||$3.50||$10,500.00|| |
Headline Trends for Celator Pharmaceuticals (NASDAQ:CPXX)
Latest Headlines for Celator Pharmaceuticals (NASDAQ:CPXX)
Celator Pharmaceuticals (CPXX) Chart for Sunday, August, 20, 2017